Previous Close | 3.1200 |
Open | 3.0900 |
Bid | 3.1300 x 900 |
Ask | 3.2300 x 900 |
Day's Range | 3.0900 - 3.2300 |
52 Week Range | 2.8000 - 35.6300 |
Volume | |
Avg. Volume | 410,872 |
Market Cap | 112.428M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7690 |
Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.77 |
SEATTLE, May 17, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.
SEATTLE, May 12, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...